Lamivudine Teva

Lamivudine, the active ingredient in Lamivudine Teva, is a nucleoside reverse transcriptase inhibitor (NRTI) presented as a tablet for oral use. It treats HIV infection and chronic hepatitis B infection in adults.

GNH USA supplies Lamivudine Teva as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lamivudine is an antiretroviral nucleoside analogue used to manage viral infections that rely on reverse transcription.

- HIV infection: reduces viral load and helps restore immune function. - Chronic hepatitis B infection: suppresses HBV replication and lowers liver inflammation. - HIV/HBV co‑infection: provides simultaneous control of both viruses in patients with dual infection.

Lamivudine is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Fatigue: feeling of tiredness or lack of energy. - Diarrhoea: loose stools, usually self‑limiting.

Serious or Rare Side Effects: - Lactic acidosis: buildup of lactate leading to metabolic disturbance. - Severe hepatotoxicity: significant liver enzyme elevation or liver failure.

Precautions are essential to minimise risk.

Lamivudine requires careful monitoring in several clinical situations.

- Renal function: assess creatinine clearance and adjust dose if needed. - Hepatic impairment: monitor liver enzymes regularly. - Pregnancy: benefits must outweigh potential unknown risks; consult obstetric specialist. - Concomitant didanosine: avoid due to increased pancreatitis risk. - Resistance testing: perform baseline HIV resistance assay before initiation. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Lamivudine may interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Didanosine: combined use raises pancreatitis risk. - Stavudine: may increase peripheral neuropathy. - Tenofovir: potential additive renal toxicity.

Moderate Interactions (Monitor Closely): - Rifampin: induces metabolism, reducing lamivudine levels. - Antacids containing aluminium or magnesium: may impair absorption. - Alcohol: can exacerbate liver injury, especially in hepatitis B patients.